Enrollment change • Combination therapy • Metastases
|
ALK (Anaplastic lymphoma kinase) • TMB (Tumor Mutational Burden) • MSI (Microsatellite instability)
|
TMB-H • MSI-H/dMMR • ALK positive • ALK mutation
|
Keytruda (pembrolizumab) • Gazyva (obinutuzumab) • vevoctadekin (ST-067)